Navigation Links
Block & Leviton LLP Investigates ViroPharma Inc. for Possible Breaches of Fiduciary Duty in Connection with Its Acquisition by Shire PLC.

BOSTON, Nov. 11, 2013 /PRNewswire/ -- Block & Leviton LLP (, a Boston-based law firm representing investors nationwide, has commenced an investigation into possible breaches of fiduciary duty by the Board of Directors of ViroPharma Inc. ("ViroPharma" or the "Company") (NASDAQ:   VPHM) concerning the proposed acquisition of the Company by U.K.-based company, Shire PLC ("Shire"), in a transaction valued at approximately $4.2 billion.  Under the terms of the transaction, Shire will acquire each ViroPharma share for $50.00, representing a paltry premium of 27% to ViroPharma's closing share price on Friday, November 8, 2013.   

The transaction was announced less than two weeks after ViroPharma announced highly positive third quarter 2013 financial results, which management described as an "extremely strong period of growth and positive momentum across our entire organization."  At that time, the Company also raised its North American net sales guidance to between $395 and $405 million. 

ViroPharma's share price has been spiking over the last year - trading between $22.12 per share on December 31, 2012 and hitting a high of $41.14 on November 7, 2013.  Indeed, in September 2013, the Company's share price rose nearly 30%.  The so-called premium appears to significantly undervalue the Company, especially considering that several companies, including Sanofi, were apparently interested in ViroPharma, which makes Cinryze for the treatment of immune disorder hereditary angioedema.  Treatments for such rare disorders can command huge prices, running into hundreds of thousands of dollars a year per patient.

Block & Leviton's investigation seeks to determine, among other things, whether ViroPharma's Directors breached their fiduciary duties by failing to maximize shareholder value in the proposed acquisition by Shire and the fairness by which the ViroPharma's Directors considered and approved the transaction.

If you are a ViroPharma shareholder and have questions about your legal rights, or if you have information relevant to this investigation, please contact attorney Steven P. Harte, at
(617) 398-5600 or email him at  

Block & Leviton is a Boston-based law firm representing investors nationwide for violations of securities laws.  The firm's lawyers have collectively been prosecuting securities cases on behalf of investors for over 50 years.  This notice may constitute attorney advertising.

Steven P. Harte, Esq.
(617) 398-5600

SOURCE Block & Leviton LLP
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Too Much Sugar on the Menu? A New Tablet Might Someday Block Those Carbs
2. ACI: Drug and Medical Device Litigation Conference - Blockbuster Faculy Announced
3. Among New Agents Entering the Unipolar Depression Market Over the Next Decade, Lundbeck/Takeda Pharmaceuticals Brintellix Has Blockbuster Potential
4. Convergence Pharmaceuticals Receives Orphan-Drug Designation for Nav1.7 Blocking Pain Drug CNV1014802
5. UK Ministers to Block Law against Headshops
6. Convergence Pharmaceuticals Announces Start of Phase II Study for Cav2.2 Selective Blocker, CNV2197944 in Pain Associated with Post-Herpetic Neuralgia
7. DSM and DecImmune Therapeutics Sign Agreement to Develop N2 Pathway Blocking Antibody
8. Stenting blocked bowel arteries saves lives
9. Blockbuster Expectations Dont Always Translate to Market Reality
10. Block Engineering Announces Collaborative Agreement with Pfizer for Next Generation Cleaning Verification Technology
11. Missouris PSE Blocking Technology Leading To Progress In Battle Against Meth
Post Your Comments:
(Date:6/26/2016)... Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced ... Act of 1976, as amended ("HSR"), with respect to ... CPXX ) expired effective June 24, 2016, ... previously announced on May 31, 2016, Jazz Pharmaceuticals and ... Jazz Pharmaceuticals has commenced a tender offer for all ...
(Date:6/24/2016)... June 24, 2016  Consumers have taken a ... have placed more emphasis on patient outcomes. ... programs in the pharmaceutical industry have evolved beyond ... pharmaceutical companies are focusing on becoming more patient-oriented ... products and services that improve health. ...
(Date:6/24/2016)... Mass. , June 24, 2016   ... Spaulding Rehabilitation Network,s Dean Center for Tick ... Physical Medicine and Rehabilitation, MIT Hacking Medicine, University ... for Innovation, today announced the five finalists of ... for Lyme disease.  More than 100 scientists, clinicians, ...
Breaking Medicine Technology:
(Date:6/25/2016)... , ... June 25, 2016 , ... Conventional wisdom preaches ... success. In terms of the latter, setting the bar too high can result in ... than just slow progress toward their goal. , Research from ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... ... ... was in a crisis. Her son James, eight, was out of control. Prone to extreme ... “When something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was ... other children and say he was going to kill them. If we were driving ...
(Date:6/24/2016)... ... June 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that ... chosen by their peers for this recognition are considered among the top 2 percent ... special honors as members of this year’s Legal Elite Hall of Fame: Miami ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... Comfort Keepers® ... American Cancer Society and the Road To Recovery® program to drive cancer patients to ... and other adults to ensure the highest quality of life and ongoing independence. ...
Breaking Medicine News(10 mins):